Patient info Search Menu

Atosiban 37.5 mg / 5 ml concentrate for solution for infusion – patient leaflet, side effects, dosage

Updated:
Key facts
Status:
Prescription only (POM)
Medicine strength:
37.5 mg / 5 ml (7.5 mg/ml)
Contains active substance:
ATC code:
Similar medicines?:

Patient leaflet - Atosiban 37.5 mg / 5 ml concentrate for solution for infusion

1. WHAT ATOSIBAN EVER PHARMA IS AND WHAT IT IS USED FOR

Atosiban EVER Pharma contains atosiban. Atosiban EVER Pharma can be used to delay the premature birth of your baby. Atosiban EVER Pharma is used in pregnant adult women, from week 24 to week 33 of the pregnancy.

Atosiban EVER Pharma works by making the contractions in your womb (uterus) less strong. It also makes the contractions happen less often. It does this by blocking the effect of a natural hormone in your body called “oxytocin” which causes your womb (uterus) to contract.

2. WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN ATOSIBAN EVER PHARMA

Do not use Atosiban EVER Pharma:

  • If you are less than 24 weeks pregnant.
  • If you are more than 33 weeks pregnant.
  • If your waters have broken (premature rupture of your membranes) and you have completed 30 weeks of your pregnancy or more.
  • If your unborn baby (foetus) has an abnormal heart rate.
  • If you have bleeding from your vagina and your doctor wants your unborn baby to be delivered straight away.
  • If you have something called “severe pre-eclampsia” and your doctor wants your unborn baby to be delivered straight away. Severe pre-eclampsia is when you have very high blood pressure, fluid retention and/or protein in your urine.
  • If you have something called “eclampsia” which is similar to “severe pre-eclampsia” but you would also have fits (convulsions). This will mean your unborn baby needs to be delivered straight away.

    • If your unborn baby has died.
    • If you have or could have an infection of your womb (uterus).
    • If your placenta is covering the birth canal.
    • If your placenta is detaching from the wall of your womb.
    • If you or your unborn baby have any other conditions where it would be dangerous to continue with your pregnancy.
    • If you are allergic to atosiban or any of the other ingredients of this medicine (listed in section 6).

Do not use Atosiban EVER Pharma if any of the above apply to you. If you are not sure, talk to your doctor, midwife or pharmacist before you are given Atosiban EVER Pharma.

Warnings and precautions

Talk to your doctor, midwife or pharmacist before you are given Atosiban EVER Pharma:

  • If you think your waters might have broken (premature rupture of your membranes).
  • If you have kidney or liver problems.
  • If you are between 24 and 27 weeks pregnant.
  • If you are pregnant with more than one baby.
  • If your contractions start again, treatment with Atosiban EVER Pharma can be repeated up to three more times.
  • If your unborn baby is small for the time of your pregnancy.
  • Your womb may be less able to contract after your baby has been born. This may cause bleeding.
  • If you are pregnant with more than one baby and/or are given medicines that can delay the birth of your baby, such as medicines used for high blood pressure. This may increase the risk of lung oedema (accumulation of fluid in the lungs).

If any of the above apply to you (or you are not sure), talk to your doctor, midwife or pharmacist before you are given Atosiban EVER Pharma.

Children and adolescents

Atosiban EVER Pharma has not been studied in pregnant women less than 18 years old.

Other medicines and Atosiban EVER Pharma

Tell your doctor, midwife or pharmacist if you are taking, have recently taken or might take any other medicines.

Pregnancy and breast-feeding

If you are pregnant and breast-feeding an earlier child, you should stop breast-feeding while you are given Atosiban EVER Pharma.

3. HOW ATOSIBAN EVER PHARMA WILL BE GIVEN

Atosiban EVER Pharma will be given to you in a hospital by a doctor, nurse or midwife. They will decide how much you need. They will also make sure the solution is clear and free from particles.

Atosiban EVER Pharma will be given into a vein (intravenously) in three stages:

  • The first injection of 6.75 mg in 0.9 ml will be slowly injected into your vein over one minute.
  • Then a continuous infusion (drip) will be given at a dose of 18 mg per hour for 3 hours.
  • Then another continuous infusion (drip) at a dose of 6 mg per hour will be given for up to 45 hours, or until your contractions have stopped.

Treatment should last no longer than 48 hours in total.

Further treatment with Atosiban EVER Pharma can be used if your contractions start again. Treatment with Atosiban EVER Pharma can be repeated up to three more times.

During treatment with Atosiban EVER Pharma, your contractions and your unborn baby’s heart rate may be monitored.

It is recommended that no more than three re-treatments should be used during a pregnancy.

The following information is intended for healthcare professionals only: (See also section 3)

Instructions for use

Before using Atosiban EVER Pharma, the solution should be examined to ensure it is clear and free from particles.

Atosiban EVER Pharma is given intravenously in three successive stages:

  • The initial intravenous injection of 6.75 mg in 0.9 ml is slowly injected into a vein over one minute.
  • A continuous infusion at a rate of 24 ml/hour is given for 3 hours.
  • A continuous infusion at a rate of 8 ml/hour is given for up to 45 hours, or until the contractions of the uterus have subsided.

The total duration of the treatment should be no more than 48 hours. Further treatment cycles of Atosiban EVER Pharma can be used should contractions recur. It is recommended that no more than three retreatments should be used during a pregnancy.

Layout Management

Neutral template version: 21.03.2024

ate / version: 25.02.2025 / 3.0_v1

Packaging type: Leaflet

Material / product name: Atosiban

Country: UK

Customer: EVER Valinject GmbH

Item number customer: Xxxx

Item number EVJ: Xxxxxxxx

Print colors: Black

XXXXXXXX

4. POSSIBLE SIDE EFFECTS

Like all medicines, this medicine can cause side effects, although not everybody gets them.

The side effects seen in the mother are generally of a mild severity. There are no known side effects on the unborn or new-born baby.

The following side effects may happen with this medicine:

Very common (affects more than 1 in 10 people)

  • Feeling sick (nausea).

Common (affects less than 1 in 10 people)

  • Headache.
  • Feeling dizzy.
  • Hot flushes.
  • Being sick (vomiting).
  • Fast heartbeat.
  • Low blood pressure. Signs may include feeling dizzy or light-headed.
  • A reaction at the site where the injection was given.
  • High blood sugar.

Uncommon (affects less than 1 in 100 people)

  • High temperature (fever).
  • Difficulty sleeping (insomnia).
  • Itching.
  • Rash.

Rare (affects less than 1 in 1,000 people)

  • Your womb may be less able to contract after your baby has been born. This may cause bleeding.
  • Allergic reactions.

You may experience shortness of breath or lung oedema (accumulation of fluid in the lungs), particularly if you are pregnant with more than one baby and/or are given medicines that can delay the birth of your baby, such as medicines used for high blood pressure.

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme (Website: www.mhra.gov.uk/yellowcard). By reporting side effects you can help provide more information on the safety of this medicine.

5. HOW TO STORE ATOSIBAN EVER PHARMA

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and the vial after “EXP”. The expiry date refers to the last day of that month.

Store in a refrigerator (2°C - 8°C).

Store in the original package in order to protect from light.

Chemical and physical in-use stability has been demonstrated for 48 hours at room temperature with and without light protection and refrigerated conditions. From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8 °C, unless dilution has taken place in controlled and validated aseptic conditions.

Do not use this medicine if you notice particulate matter and discoloration prior to administration.

6. CONTENTS OF THE PACK AND OTHER INFORMATION

What Atosiban EVER Pharma contains

  • The active substance is atosiban. Each vial (5 ml) of 37.5 mg/5 ml concentrate for solution for infusion contains 37.5 mg of atosiban (as acetate). Each ml of the concentrate for solution for infusion contains 7.5 mg atosiban (as acetate).
  • The other ingredients are mannitol, hydrochloric acid 1 M (for pH adjustment), sodium hydroxide (for pH adjustment) and water for injections.

What Atosiban EVER Pharma looks like and contents of the pack

Atosiban EVER Pharma 37.5 mg/5 ml concentrate for solution for infusion is a clear, colourless solution without particles.

One carton contains one vial containing 5 ml solution.

The container closure system is composed of one colourless glass vial, closed with a bromobutyl rubber stopper and an aluminium crimp cap with a plastic flip-off.

Marketing Authorisation Holder

EVER-Valinject GmbH

Oberburgau 3

4866 Unterach, Austria

Manufacturer

EVER Pharma Jena GmbH

Brüsseler Str. 18

07747 Jena, Germany

This leaflet was last revised in July 2023.

Preparation of the intravenous infusion solution.

The intravenous infusion is prepared by diluting Atosiban EVER Pharma 37.5 mg/5 ml concentrate for solution for infusion in sodium chloride 9 mg/ml (0.9%) solution for injection, Ringer‘s lactate solution or 5% w/v glucose solution. This is done by removing 10 ml of solution from a 100 ml infusion bag and replacing it with 2 vials of 5 ml Atosiban EVER Pharma 37.5 mg/5 ml concentrate for solution for infusion to obtain a concentration of 75 mg atosiban in 100 ml. If an infusion bag with a different volume is used, a proportional calculation should be made for the preparation.

Atosiban EVER Pharma should not be mixed with other medicinal products in the infusion bag.

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PL 46654/0002

Last revision stated in the text: July 2023 · MHRA data as of 13 October 2026

What the sections and the side effect frequencies mean: How to read a patient leaflet

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Atosiban 37.5 mg / 5 ml concentrate for solution for infusion

What these facts mean

Prescription needed?? Yes, prescription-only medicine (POM)
Active substance? Atosiban
Strength? 37.5 mg / 5 ml (7.5 mg/ml)
Pharmaceutical form? Solution for infusion
Clear, colourless solution without particles.
pH: 4.0 to 5.0
How is it taken? Intravenous
Excipients? Mannitol, Hydrochloric acid 1M (for pH adjustment), Sodium hydroxide (for pH adjustment), Water for injections
Is it available?? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Shelf life? 3 years
Chemical and physical in-use stability has been demonstrated for 48 hours at room temperature with and without light protection and refrigerated conditions. From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8 °C, unless dilution has taken place in controlled and validated aseptic conditions.
Storage Store in a refrigerator (2°C - 8°C).
Store in the original package in order to protect from light.
For storage conditions after first opening and dilution of the medicinal product, see section 6.3.
Drug group (ATC)? Other gynecologicals
  1. G Genito urinary system and sex hormones
    1. G02 Other gynecologicals
      1. G02C Other gynecologicals
        1. G02CX Other gynecologicals
          1. G02CX01 atosiban
Marketing authorisation? PL 46654/0002 (first authorised 29 September 2016)
Marketing authorisation holder? EVER Valinject GmbH
Codes? BNF 07010300

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 11.1.0 of 9 November 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.